Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Isotretinoin for Melasma
NCT06201624Phase 1Recruiting
- Sponsor
- Zagazig University
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of isotretinoin in melasma (2 arms), sponsored by Zagazig University. Primary endpoints: Response to treatment at 3 months and Time to complete clearance at 12 weeks. Started Mar 2023; status: recruiting.
02
Drugs
isotretinoin
03
Conditions
melasma
Beyond the preview
Go deeper on NCT06201624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06201624.